Filing summary
Filing identity: The supplied filing is DelMar Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2017, not a Tuhura Biosciences, Inc. filing for 2016 Q3. The figures below summarize the filing provided; confirm the issuer and reporting period before relying on them. Amounts are in U.S. dollars.
Business context and reporting period
DelMar was a clinical-stage cancer drug developer focused primarily on VAL-083 for glioblastoma (GBM), with research in other cancers and certain exclusive commercial rights in China. The filing reports the three and nine months ended March 31, 2017, compared with the same periods in 2016; the balance sheet compares March 31, 2017 with June 30, 2016.
Financial performance and liquidity
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue | No revenue reported | No revenue reported |
| Research and development expense | $1.086 million; prior year $0.790 million | $2.940 million; prior year $2.183 million |
| General and administrative expense | $0.698 million; prior year $0.630 million | $2.586 million; prior year $1.995 million |
| Net loss | $1.868 million; prior year $1.140 million | $5.481 million; prior year $5.408 million |
| Loss per share | $0.18; prior year $0.10 | $0.54; prior year $0.50 |
| Cash used in operating activities | Not separately reported for the quarter | $4.570 million; prior year $3.592 million |
There are no meaningful revenue or profit margins to report because the company had not commercialized its candidate and reported no revenue. Cash and cash equivalents were $2.100 million at March 31, down from $6.157 million at June 30, 2016. Working capital was $1.454 million, compared with $5.692 million. Total assets were $2.341 million and total liabilities were approximately $1.111 million. The filing reports no conventional borrowings; warrant-related derivative liabilities totaled $0.249 million.
The company reported an accumulated deficit of $38.402 million. Operating cash use increased year over year, while the nine-month net loss changed only modestly; expenses rose, and noncash fair-value movements in warrants and options affected reported results.
Material changes and unusual items
- Quarterly R&D expense rose 37% and G&A expense rose 11% year over year. Management attributed the R&D increase mainly to clinical-trial preparation, manufacturing, intellectual-property work, personnel, and travel; G&A increases included professional fees and personnel.
- For the nine-month period, R&D expense increased 35% and G&A expense increased 30%. Operating cash use rose 27% year over year.
- Quarterly loss included a $77,479 loss from changes in fair value of stock-option and derivative liabilities, compared with a $276,584 gain in the prior-year quarter. These noncash valuations can cause reported losses to fluctuate.
- Series B preferred dividends were paid in common shares: $209,811 for the quarter and $676,865 for the nine-month period. The Series B shares also carry a 9% cumulative dividend and a low-single-digit royalty arrangement on covered product sales.
- Common shares outstanding were 11,675,174 at March 31, 2017; 13,461,645 were reported outstanding as of May 12, 2017. The latter reflects subsequent share issuance, including the public offering.
Outlook, risks, and contingencies
- Financing and runway: In April 2017, after quarter-end, the company completed an offering of 2,769,232 common shares and warrants for gross proceeds of approximately $9.0 million and net proceeds of approximately $8.0 million. Management estimated the funds would support planned operations for 18–24 months; the financial-statement note also states management expected to fund operations beyond the next twelve months. These are estimates, not guarantees.
- Clinical development: Management planned to advance VAL-083 toward a pivotal Phase 3 trial, STAR-3, in recurrent GBM after failure of temozolomide and bevacizumab. A proposed protocol had been submitted to the FDA; the planned study was approximately 180 patients, randomized 2:1 against physician’s-choice salvage chemotherapy. The filing does not establish that the pivotal trial had begun by the report date.
- Clinical evidence and safety: Management cited Phase 1–2 results, including median survival of 8.35 months after bevacizumab failure in a 22-patient subgroup receiving assumed therapeutic doses. The company cautioned that the study was small and uncontrolled. Myelosuppression, particularly low platelets, was the key dose-limiting toxicity described.
- Other programs: A Phase 2 study with MD Anderson in recurrent MGMT-unmethylated GBM had begun, and a separate China study in newly diagnosed patients was awaiting required approval. A Duke research collaboration was announced after quarter-end.
- Funding risk: The company had no near-term revenue prospect and depended on additional financing to continue research and development. Management warned that unavailable or unfavorable financing could require delaying, reducing, or stopping programs.
- Controls and legal matters: Management concluded disclosure controls were not effective at period-end because of a material weakness previously reported in the 2016 Form 10-K. No material changes to internal control were reported during the quarter. The filing reported no legal proceedings.
Important facts for investors to verify
- Confirm that DelMar Pharmaceuticals and the March 31, 2017 reporting period—not Tuhura Biosciences and 2016 Q3—are the intended subject.
- Verify the post-quarter offering’s net proceeds, share and warrant terms, and resulting dilution; the filing reports approximate net proceeds of $8.0 million.
- Check subsequent cash use and whether management’s 18–24 month runway estimate remains achievable.
- Track FDA feedback, trial initiation, enrollment, endpoints, and results for STAR-3; distinguish proposed plans from completed milestones.
- Review the limitations of the early clinical survival data and the safety profile, particularly hematologic toxicity.
- Assess the status of the disclosed material weakness and any later remediation or auditor commentary.